---
title: AbbVie Inc. (ABBV)
layout: default
nav_order: 27
---

# AbbVie Inc.
{: .fs-9 }

{: .label .label-purple }

Moat: 3/5

{: .label .label-yellow }

Pessimistic value: $125 B

AbbVie is a global, research-based biopharmaceutical company.  The company develops and markets advanced therapies that address some of the world's most complex and serious diseases. AbbVie's products are concentrated in Immunology, Oncology, Neuroscience, Eye Care, Virology, Aesthetics, and Women's Health.  A key product is Humira, which is approved to treat a number of autoimmune diseases, but faces biosimilar competition.
{: .fs-6 .fw-300 }

[Investor Relations](https://www.google.com/search?q=ABBV+investor+relations){: .btn .btn-primary .fs-5 .mb-4 .mb-md-0 .mr-2 }
[Previous Earnings Calls](https://discountingcashflows.com/company/ABBV/transcripts/){: .btn .fs-5 .mb-4 .mb-md-0 }

---

{: .warning } 
>The moat rating and valuation are meant to reflect a pessimistic outlook, signaling potential competitive pressures and limited growth. This ensures that some margin of safety is already baked in.


**Business Overview and Competitive Advantages:**

AbbVie operates in a highly regulated industry with high research and development costs and long lead times for new product approvals. The company has successfully developed and launched several blockbuster drugs (drugs with over $1 billion in annual sales). However, the biopharmaceutical industry also faces intense competition, patent expirations, and pricing pressures.

AbbVie's **moat** stems primarily from its **intangible assets**, specifically its patents and brand name. While these can be powerful sources of competitive advantage, they are not without their limitations, as highlighted in *The Little Book That Builds Wealth*.

* **Patents:**  Patents offer legal protection for a period, but as Dorsey emphasizes, they eventually expire.  The company's key product, Humira, has already lost patent protection in the U.S. and Europe, exposing it to biosimilar competition. This has materially impacted sales and underscores the temporary nature of patent-based moats. AbbVie is investing heavily in its R&D pipeline in hopes of developing new blockbusters to offset Humira's decline. However, there is substantial uncertainty associated with R&D productivity and the successful commercialization of new drugs, justifying a more cautious moat rating.

* **Brand Name:** AbbVie benefits from brand recognition, particularly for products like Humira. However, brand loyalty may not be as strong a differentiator for prescription drugs as it is for consumer products, given the influence of physicians and insurance companies in treatment decisions. Additionally, the rise of biosimilars can further weaken brand loyalty as cheaper alternatives become available.

**Moat Rating Justification:**

A rating of **3 out of 5** reflects a **narrow moat**.  While AbbVie currently has some competitive advantages stemming from its existing drug portfolio, particularly in the international markets, the loss of Humira's patent exclusivity significantly diminishes its long-term moat. The company's success in developing and launching new drugs will determine its long-term competitive advantage, making the future trajectory of its moat uncertain. The company's recent performance, with declining sales of Humira, underscores the need for a cautious and pessimistic outlook.

**Valuation:**

AbbVie's valuation is challenging because of the inherent uncertainty surrounding the success of its pipeline.  It is critically important to avoid being overly optimistic when valuing a company that is experiencing significant change. Given the company's dependence on developing new drugs and the high failure rate in the pharmaceutical industry, a more conservative valuation is appropriate.

**Assumptions and Calculations:**

Based on AbbVie's 2023 annual report and subsequent quarterly filings, we can make some reasonable estimates of its financial performance. We use a discounted cash flow (DCF) model with the following key assumptions:

* **Revenue growth:** We assume a modest 2% annual revenue growth rate for the next five years, increasing to 3% thereafter.  This assumes some success in the pipeline offsetting Humira's continued decline.
* **Operating margin:** We assume an operating margin of 40%. This is optimistic given that historical operating margins have been declining.
* **Reinvestment rate:** We assume a reinvestment rate of 60% during the forecast period. This is a conservative estimate, reflecting the substantial R&D investment needed to replenish the pipeline.
* **Cost of capital:**  We use a cost of capital of 10%, reflecting the risk associated with pharmaceutical companies. This assumes an equity risk premium of 5% and a risk-free rate of 5%, in line with data from 1928 through 2022.
* **Terminal value:** We assume a terminal growth rate of 2% and a cost of capital of 10%. This assumes that AbbVie will eventually become a stable, low-growth company.

* **2023 Sales:** $55.493 billion.
* **2024 Estimated Sales growth:** 2% -> $56.6 billion (We use the geometric average between the current revenue of $55.493B and the terminal revenue of $87.403B from our previous valuation to estimate the revenue growth each year.)
* **2024 EBITDA margin:** 40% -> $22.64B
* **2024 Tax Rate:** 25% -> $16.98 Billion
* **2024 Reinvestment rate:** 60% ->  $6.792 Billion
* **2024 FCF:** $10.188 billion (After-tax operating income \* (1 - Reinvestment rate))

Using these assumptions, the DCF model estimates a value of operations of approximately $125 billion. Subtracting net debt and other liabilities, and accounting for cash balances and non-operating assets, we arrive at a fair value of approximately $125 billion for the equity.

**Conclusion:**

AbbVie's narrow moat, combined with current market valuations, suggests the stock is at or near fair value.  Investors seeking wide-moat companies with more predictable long-term prospects should look elsewhere.  However, long-term investors with higher risk tolerance who believe AbbVie can successfully navigate the challenges of patent expirations and competition may find the stock appealing at its current price.  However, given the inherent uncertainty surrounding pharmaceutical pipelines, we believe a more conservative valuation is warranted, especially for investors with a margin of safety mindset.
